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Abstract
AIM
To investigate any changing trends in the etiologies of 
hepatocellular carcinoma (HCC) in Argentina during the 
last years. 
METHODS
A longitudinal cohort study was conducted by 14 regional 
hospitals starting in 2009 through 2016. All adult patients 
with newly diagnosed HCC either with pathology or 
imaging criteria were included. Patients were classified 
as presenting non-alcoholic fatty liver disease (NAFLD) 
either by histology or clinically, provided that all other 
etiologies of liver disease were ruled out, fatty liver 
was present on abdominal ultrasound and alcohol 
consumption was excluded. Complete follow-up was 
assessed in all included subjects since the date of HCC 
diagnosis until death or last medical visit.
RESULTS
A total of 708 consecutive adults with HCC were 
included. Six out of 14 hospitals were liver transplant 
centers (n  = 484). The prevalence of diabetes mellitus 
was 27.7%. Overall, HCV was the main cause of liver 
disease related with HCC (37%) including cirrhotic 
and non-cirrhotic patients, followed by alcoholic liver 
disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 
5.4% infection, cholestatic disease and autoimmune 
hepatitis 2.2%, and other causes 9.9%. A 6-fold 
increase in the percentage corresponding to NAFLD-
HCC was detected when the starting year, i.e. , 2009 
was compared to the last one, i.e. , 2015 (4.3% vs  
25.6%; P  < 0.0001). Accordingly, a higher prevalence 
of diabetes mellitus was present in NAFLD-HCC group 
61.7% when compared to other than NAFLD-HCC 
23.3% (P  < 0.0001). Lower median AFP values at 
HCC diagnosis were observed between NAFLD-HCC 
and non-NAFLD groups (6.6 ng/mL vs  26 ng/mL; P  = 
0.02). Neither NAFLD nor other HCC etiologies were 
associated with higher mortality.
CONCLUSION
The growing incidence of NAFLD-HCC documented 
in the United States and Europe is also observed in 
Argentina, a confirmation with important Public Health 
implications. 
Key words: Hepatocellular carcinoma; Etiology; Fatty 
liver; South America
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Despite the increasing incidence of non-
alcoholic fatty liver disease (NAFLD) and NAFLD related 
hepatocellular carcinoma (HCC) in developed countries, 
information related with the burden of NAFLD-HCC 
in developing countries as those in South America is 
lacking. In this multicenter cohort study from Argentina 
including patients with HCC, while HCV and alcoholic 
related cirrhosis were the most frequent causes of 
HCC between 2009 and 2016, NAFLD-HCC had a 
6-fold increased during the same period. This changing 
scenario was observed without precluding any specific 
etiology of liver disease. NAFLD might become one of 
the first HCC related causes in the coming decades; an 
issue to be consider with effective prevention strategies.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the second leading 
cause of cancer related death worldwide and the 
main cause of death among patients with cirrhosis[1,2]. 
The incidence of HCC varies according to geographic 
location, closely linked to the prevalence of chronic 
hepatitis C (HCV) or B virus (HBV) infections as well as 
the prevalence of alcoholic liver disease.
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With the advent of new direct antiviral drugs (DAAs) 
for HCV treatment, epidemiological changes have been 
reported in the natural history of liver disease[3]. First, 
the improvement of decompensated cirrhotic patients, 
the consequence and the increasing rate of delisting 
from liver transplantation (LT) waitlist after eradication 
of HCV. On the other hand, a lower wait-listing ratio of 
patients with HCV decompensated cirrhosis has been 
observed[3]. However, the proportion of patients listed 
for LT with HCC has been increased during the era of 
DAAs[4].
This increasing incidence of HCC has been attributed 
in developed countries due to a stepwise increase in the 
incidence of non-alcoholic fatty liver disease (NAFLD), 
recognized as an emergent cause of end stage liver 
disease and HCC[4,5]. NAFLD is the expression of a 
pandemic disease, which is associated with the metabolic 
syndrome, obesity and type 2 diabetes. Indeed, it is 
estimated that during the next 20 years, non-alcoholic 
steatohepatitis (NASH), the progressive form of NAFLD, 
will constitute the most frequent cause of cirrhosis and 
HCC in developed countries[6].
However, HCC epidemiological reports from develo-
ping areas, including South America, have been hetero-
geneous[7-14]. Furthermore, no studies have tackled the 
issue of changing trends in etiologies of HCC over time. 
Our present aim was to evaluate changes in etiology of 
HCC in Argentina during the last seven years, focusing 
on two aspects, the potential changes associated 
with DAA’s era of HCV treatment, as well as changes 
associated with NAFLD-HCC.
MATERIALS AND METHODS
This longitudinal observational cohort study was con-
ducted between January 1 2009 and January 1 2016 
in 14 regional hospitals from Argentina. Sites were 
instructed to enroll all eligible patients on a sequential 
basis and data to be recorded from medical charts into 
a web-based electronic system. 
A cohort of consecutive adult patients (> 17 years of 
age) with newly diagnosed HCC was included. Criteria 
for inclusion required patients to have newly diagnosed 
HCC either by pathological criteria or imaging evaluation 
as recommended by international guidelines[15,16].
Etiologies of HCC considering the primary diagnosis 
of liver disease included HCV (anti HCV positivity), 
HBV (hepatitis B surface antigen positivity), alcoholic 
liver disease (alcohol intake exceeding 30 g), NAFLD, 
cryptogenic cirrhosis (CC), cholestatic liver diseases 
(i.e., primary biliary cholangitis, primary and secondary 
sclerosing cholangitis), autoimmune hepatitis and other 
causes including metabolic diseases or miscellaneous 
causes (e.g., hereditary hemochromatosis, Wilson di-
sease, toxic liver disease). 
NAFLD diagnosis was achieved on histological ground 
or clinically according to international guidelines[17]. Pa-
tients were classified as presenting clinical NAFLD pro­
vided that all other etiologies of liver disease were ruled 
out, fatty liver was present on abdominal ultrasound 
(US) and alcohol consumption was excluded (30 g for 
men and 20 g women). Histological NAFLD was defined 
by an excessive hepatic fat accumulation associated 
with insulin resistance and the presence of > 5% of 
steatosis in liver biopsy. NAFLD included non-alcoholic 
fatty liver and NASH. 
Baseline patient and tumor characteristics were 
recorded at HCC diagnosis including patients demo-
graphics, previous US surveillance, performance status 
(Eastern Cooperative Oncology Group, ECOG grade 
0-4)[18], liver fibrosis stage (I­IV) assessed by liver biopsy 
elastography, other non-invasive measurements or by 
clinical data (presence of esophageal varices or ascites or 
splenomegaly > 120 mm diameter, or features related 
to portal hypertension), Child Pugh score and laboratory 
variables. Serum alpha-fetoprotein (AFP) levels at 
diagnosis were categorized in three cut-off values: ≤ 
100 ng/mL, 101-1000 ng/mL and > 1000 ng/mL[19].
Specific major co­morbidities for each subject were 
also registered including: diabetes mellitus, severe 
chronic pulmonary disease, coronary heart disease 
and congestive heart disease, previous ischemic or 
hemorrhagic stroke, peripheral vascular disease, chronic 
kidney failure (glomerular filtration rate < 30 mL/min) 
and non-HCC cancer.
Tumor characteristics and treatments performed 
during follow-up were also registered. Computed tomo-
graphy (CT) or magnetic resonance images (MRI) were 
included to assess tumor burden, which was classified 
according to Barcelona Clinic Liver Cancer staging (BCLC 
criteria)[16]. 
Study end-points
Our study focused on changing trends of HCC etiologies 
at different periods from 2009 to 2016. A stratified 
per-etiology analysis and per Liver Transplant (LT) 
and non-LT centers was performed. Complete patient 
follow­up was assessed in all included subjects from 
HCC diagnosis until death or last medical visit. 
All procedures followed were in accordance with 
the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines[20]. This 
study was approved by the Austral University School 
of Medicine and by all 14 centers; complied with the 
ethical standards (institutional and national) and 
with Helsinki Declaration of 1975, as revised in 2008. 
Patient consent was obtained in all subjects included.
Statistical analysis
Institutional clinical research committee reviewed 
the statistical methods of this study. Categorical data 
were compared using Fisher’s exact test (2-tailed) 
or χ 2 test. Continuous variables were compared with 
Student’s t-test or Mann-Whitney U test according to 
their distribution, respectively. For survival analysis, 
Cox regression multivariate analysis estimating hazard 
ratios (HR) and 95%CI for baseline variables related 
with 5-year mortality was performed. Confounding 
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effect was defined when more than 20% of change 
in the crude HR. Kaplan Meier survival curves were 
compared using the log-rank test (Mantel-Cox) and 
adjustment of each final model was evaluated with 
proportional hazards through graphic and statistical 
evaluation (Schoenfeld residual test). Calibration was 
assessed by comparison of observed and predicted 
curves and evaluation of the goodness of fit of the 
model by Harrell’s c-statistic index. Collected data was 
analyzed using STATA 10.0.
RESULTS
A total of 708 consecutive adult patients with newly 
diagnosed HCC from 14 centers were included. Out of 14 
hospitals, 6 were LT centers, which contributed with the 
follow-up of 484 patients (68.4% of the study cohort). 
Baseline patients and tumor characteristics
Table 1 describes the baseline patients’ characteristics. 
Non-cirrhotic patients accounted for 12.6% of the 
included cohort (n = 89). Overall prevalence of 
diabetes mellitus (DBT) was 27.7% (Table 1).
Overall, HCV was the most frequent cause of 
underlying liver disease. Etiology of HCC in cirrhotic 
patients was as follows: 37% HCV infection (n = 262), 
20.8% alcoholic liver disease (n = 147), 11.4% NAFLD 
(n = 81), 9.6% cryptogenic cirrhosis/liver disease 
(CC, n = 68), 5.4% HBV infection (n = 38), 2.2% of 
cholestatic disease and autoimmune hepatitis (n = 
16), and 9.9% other causes (n = 60) (Table 2). Most 
frequent HCV genotypes (G) were G1b (n = 88), 
followed by G1a (n = 47), G3 (n = 27), G2 (n = 8) 
and G4 (n = 2) (Figure 1). 
Etiology of HCC among non-cirrhotic patients 
included cryptogenic liver disease in 52.8% (n = 47), 
chronic HCV infection in 21.3% (n = 19), NAFLD in 
10.1% (n = 9), chronic HBV infection in 9.0% (n = 8), 
altered iron metabolism in 4.5% (n = 4) and chronic 
alcohol consumption in 2 patients.
At HCC diagnosis, 4.2% (n = 30), 43.1% (n = 
305), 21.3% (n = 151), 9.5% (n = 67) and 21.9% (n 
= 155) of the patients were within BCLC 0, A, B, C and 
D stages, respectively. Median serum AFP was 23.0 
ng/mL (IQR 5.0; 337 ng/mL, Table 1).
Etiologies of HCC stratified by periods of time
Changes over time for each HCC etiology were analyzed 
in order to observe any epidemiological changes during 
the entire period. HCV related HCC was the most 
frequent etiology along the whole observation period. 
No significant changes were observed in the proportion 
of HCV-HCC (Table 2). The second most frequent cause 
of HCC was alcoholic liver disease, remaining stable 
during the observation period. On the other hand, 
a striking 6-fold increase in the proportion of HCC-
NAFLD cases was observed since 2009 to 2016 (4.3% 
Table 1  Patients’ baseline characteristics
Variable P  values
Age, yr (± SD) 62 ± 10
Male gender, n (%) 537 (75.9)
Non-cirrhotic liver, n (%)   89 (12.6)
Child Pugh A/B/C, n (%) 352 (49.7)/238 (33.6)/118 (16.7)
Comorbidities, n (%) 299 (42.2)
Diabetes mellitus, n (%) 196 (27.7)
Ascites, n (%) 253 (35.7)
  Mild 144 (20.3)
  Moderate-severe 109 (15.4)
Encephalopathy, n (%) 147 (20.8)
  Grade Ⅰ-Ⅱ 137 (19.3)
  Grade Ⅲ-Ⅳ 10 (1.4)
Esophageal varices, n (%) 394 (56.7)
ECOG 0-2/3-4, n (%) 637 (89.9)/71 (10.1)
Median HCC number, (IQR) 1.0 (1.0-2.0)
Largest HCC diameter, mm (IQR) 53 ± 37
Within Milan, n (%) 334 (46.9)
Bilobar involvement, n (%) 159 (22.1)
Diffuse HCC pattern, n (%) 28 (3.9)
Median AFP, ng/mL (IQR) 23.0 (5.0-337.0)
≤ 100 ng/mL, n (%) 476 (66.3)
101-1000 ng/mL, n (%) 128 (17.7)
> 1000 ng/mL, n (%) 115 (16.0)
Tumor vascular invasion, n (%)   74 (10.4)
Extrahepatic disease, n (%) 48 (6.8)
ECOG: Eastern Cooperative Oncology Group; HCC: Hepatocellular 
carcinoma; AFP: alpha-fetoprotein.
HCV
39%
n = 262
Other
9%
HBV
6%
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ALCOHOL
22%
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Figure 1  Etiologies oh hepatocellular carcinoma in the overall cohort and 
hepatitis C virus genotypes. HCV was the main cause of liver disease related 
with hepatocellular carcinoma including cirrhotic and non-cirrhotic patients. 
Distribution of known HCV genotypes (G) showed that G1b was the most 
frequent (n = 88), followed by G1a (n = 47), G3 (n = 27), G2 (n = 8) and G4 (n = 
2). HCV: Hepatitis C virus.
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vs 25.6%; P < 0.0001). Moreover, NAFLD represented 
the second cause of HCC in 2015 together with 
alcoholic liver disease (Table 2). 
We further considered patients with cryptogenic 
cirrhosis and DBT (n = 22/68) as potentially NAFLD. 
This new group was merged with NAFLD accounting 
for 14.5% (n = 103) of the entire cohort. Its incidence 
increased from 8.6% in 2009 to 16.2% in 2014 and 
25.6% in 2016, respectively (P = 0.014). Prevalence 
of DBT was similar between HCC cirrhotic and non-
cirrhotic patients (23.2% vs 28.2%; P = 0.38).
Comparative analysis between NAFLD and non-NAFLD 
HCC patients
A comparative analysis between NAFLD and non-NAFLD-
HCC was performed. Mean age was similar in both 
groups. Only a small proportion of patients were non-
cirrhotic (8.6% NAFLD vs 9.9% non-NAFLD; P = 0.72). 
There were no significant differences regarding Child 
Pugh score, MELD score and presence of clinically 
significant portal hypertension (Table 3). 
Comorbidities were most frequently observed 
in the NAFLD group, particularly there was a higher 
prevalence of diabetes mellitus (DBT) (61.7% vs non-
NAFLD 23.3%; P < 0.0001). When a stratified analysis 
was performed comparing the prevalence of DBT, there 
were no changes observed ranging from 8.9% in 2009 
to 17.3% in 2012 (P = 0.89). As previously shown, the 
increasing proportion of NAFLD in the overall cohort was 
not in parallel with an increasing prevalence of DBT.
Regarding HCC burden, there were no significant 
differences with previous surveillance (NAFLD 59.5% 
vs non-NAFLD 57.9%; P = 0.81) and BCLC staging at 
HCC diagnosis. Median AFP was lower in the NAFLD-
HCC when compared to non-NAFLD group (6.6 ng/mL 
vs 26 ng/mL; P = 0.02) (Figure 2).
Etiology of HCC in non-liver transplant vs liver 
transplant centers
Among LT centers, the main etiology of HCC during 2009 
Table 2  Underlying etiologies of liver disease per year (frequencies)
HCV HBV Alcohol NASH CC Cholestasis AI Other1 Total
2009   24 (34.3)     7 (10.0)   18 (25.7) 3 (4.3)     9 (12.9) 0 0     9 (12.9)   70
2010   51 (48.6)   5 (4.8)   16 (15.2) 5 (4.8)   12 (11.4)   3 (2.9) 1 (0.9)   12 (11.5) 105
2011   34 (35.6)   5 (5.3)   26 (27.4) 10 (10.5)   9 (9.5)   1 (1.0) 1 (1.0)   7 (6.4)   95
2012   43 (38.0)   5 (4.4)   21 (18.6) 14 (12.4) 10 (8.8)   3 (2.6) 0   5 (8.0) 113
2013   43 (33.1)   9 (6.9)   24 (18.5) 14 (10.8)   17 (13.1)   2 (1.5) 1 (0.8)   13 (10.0) 130
2014   43 (36.7)   4 (3.4)   22 (18.8) 15 (12.8)   9 (7.7)   3 (2.6) 0   16 (13.7) 117
2015   24 (30.8)   3 (3.8)   20 (25.6) 20 (25.6)   2 (2.6)   1 (1.3) 0   4 (5.2)   78
Total (%) 262 (37.0) 38 (5.4) 147 (20.8) 81 (11.4) 68 (9.6) 13 (1.8) 3 (0.4) 60 (9.9) 708
1Other causes of cirrhosis, Hemochromatosis. NASH: Non-alcoholic steatohepatitis; AI: Autoimmune; CC: Cryptogenic cirrhosis; HBV: Hepatitis B virus; 
HCV: Hepatitis C virus.
Table 3  Comparative analysis between non alcoholic fatty liver disease and other than non alcoholic fatty liver disease
Variable NAFLD n  = 81 (11.4%) Non-NAFLD n  = 627 (88.6%) P value
Age, yr (± SD) 63 ± 8 62 ± 4 0.39
Gender, male, n (%) 68 (83.9) 469 (74.9) 0.06
Non-cirrhotic liver, n (%) 7 (8.6) 62 (9.9) 0.72
Child Pugh A/B/C, n (%) 41 (50.6)/32 (39.5)/8 (9.9) 311 (49.6)/206 (32.8)/110 (17.5) 0.15
Comorbidities, n (%) 60 (74.1) 239 (38.1)  < 0.0001
Diabetes mellitus, n (%) 50 (61.7) 146 (23.3)  < 0.0001
Median AFP level, ng/mL  6.6 (4-380) 26 (5.3-332)   0.017
AFP > 1000 ng/mL, n (%)  9 (12.0)   97 (16.1) 0.34
Ascites, n (%)
  Mild 17 (21.0) 127 (20.3) 0.7
  Moderate-severe 10 (12.3)   99 (15.8) 0.7
Encephalopathy, n (%)
  Grade Ⅰ-Ⅱ 18 (22.2) 119 (19.0) 0.2
  Grade Ⅲ-Ⅳ 3 (3.7) 7 (1.1) 0.2
Esophageal varices, n (%) 50 (63.3) 344 (55.8) 0.5
ECOG 0-2, n (%) 73 (90.1) 564 (89.9)   0.96
Median HCC number, (IQR) 1 (1-2)   1 (1-2)   0.38
Largest HCC diameter, mm (IQR) 55 ± 37 52 ± 37   0.51
Within Milan, n (%) 38 (46.9) 295 (47.0)   0.98
Bilobar involvement, n (%) 16 (19.7) 142 (22.7)   0.82
Diffuse HCC pattern, n (%) 3 (3.7) 20 (3.2)   0.82
AFP: Alpha-fetoprotein; MELD: Model for end stage liver disease; AFLD: Alcoholic fatty liver disease; Non-NAFLD: Other than NAFLD (includes all other etiologies).
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was HCV, remaining stable over the years, becoming the 
second cause of HCC in 2015. Furthermore, the main 
cause of HCC during 2015 was NAFLD, showing 6-fold 
increase from 2009 to 2014 and 2015 (5.8% vs 13.9% 
vs 36.9%, respectively; P < 0.0001). Alcoholic liver 
disease was the second overall cause of HCC, which was 
unchanged since 2009 among the different periods. 
In non-transplant centers, HCV was the most fre-
quent cause of HCC during all analyzed periods, followed 
by alcoholic liver disease. No significant changes in the 
proportion of patients with HCV or alcoholic liver disease 
were observed in this group. An increasing number of 
NAFLD-HCC cases were observed, which was lower than 
that observed in LT centers (LT centers 5.8% to 36.9%; 
P < 0.0001 vs non-LT centers 0% to 9%; P = NS).
Etiologies and impact on patient survival
Both uni and multivariate Cox regression analysis were 
performed as shown on Table 4 evaluating baseline 
patient and HCC characteristics associated with worse 
survival. Neither the presence of comorbidities (HR 
1.08; CI 0.86; 1.37) nor DBT were related to mortality 
(HR 0.83; CI 0.63; 1.08). When considering different 
HCC etiologies, neither NAFLD nor viral etiologies 
presented higher mortality rates during the follow-up 
(Figure 3).
On the multivariate model, independent variables 
associated with death were age HR 1.03 (CI 1.01; 1.04), 
BCLC 0-A stages vs non 0-A stages HR 0.50 (CI 0.37; 
0.68), Child Pugh B or C vs A HR 1.54 (CI 1.61; 2.05), 
HR 2.59 (CI 1.84; 3.66), respectively; AFP > 1000 ng/
mL at HCC diagnosis HR 2.09 (CI: 1.52; 2.87) and HCC 
vascular invasion HR 2.83 (CI: 1.75; 3.53) (Table 5).
DISCUSSION
To the best of our knowledge this is the first multicenter 
cohort study from a South American country evaluating 
longitudinal changes in etiologies of HCC. This changing 
etiologic scenario documented in developed countries 
is replicated in developing ones[4,5]. The documented 
increase in NAFLD-HCC in our study entails itself a 
Table 4  Baseline pre-treatment variables associated with 5-year mortality, univariate cox regression
Variable 5-yr mortality rate, (%) Hazard ratio (95%CI) P  value
Age (yr) 1.02 (1.01; 1.04) < 0.0001
Gender: male (n = 537)   42.7 1.08 (0.83; 1.42) 0.58
Female (n = 170)   42.3
Comorbidity
  Yes (n = 299)   45.1 1.08 (0.86; 1.37) 0.49
  No (n = 409)   40.6
Diabetes mellitus
  Yes (n = 196)   38.8 0.83 (0.63; 1.08) 0.17
  No (n = 512) 44
NAFLD
  Yes (n = 81)   35.9 1.16 (0.81; 1.69) 0.41
  No (n = 627)   56.9
ECOG 0-2
  Yes (n = 637)   37.9 0.19 (0.14; 0.26)     0.0001
  No (n = 71)   84.5
BCLC 0-A
  Yes (n = 335) 26 0.29 (0.23; 0.38)     0.0001
  No (n = 373)   57.4
Cirrhosis
  Yes (n = 639)   42.9
  No (n = 69)   39.1 0.86 (0.58; 1.28) 0.45
Child Pugh
  A (n = 352)   34.5 -
  B (n = 238)   41.6 1.38 (1.06; 1.83)   0.019
  C (n = 118)   68.6 3.23 (2.41; 4.34)     0.0001
Clinically significant portal hypertension
  Yes (n = 484)   40.2 1.22 (0.94; 1.57) 0.13
  No (n = 224)   43.7
AFP > 1000 ng/mL
  Yes (n = 106)   64.1 3.09 (2.31; 4.15)    0.0001
  No (n = 569)   39.5
Tumor vascular invasion
  Yes (n = 74) 77 4.74 (3.48; 6.44)     0.0001
  No (n = 634)   38.5
Extrahepatic tumor disease
  Yes (n = 48)   70.8 3.29 (2.25; 4.81)     0.0001
  No (n = 660)   40.5
Normal Values: Alpha-fetoprotein 0.6-4.4 ng/mL. AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; ECOG: Eastern cooperative oncology group; 
HCC: Hepatocellular carcinoma; LT: Liver transplantation; WL: Waiting list; NAFLD: Non-alcoholic fatty liver disease.
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challenging impact on Public Health worth to be con-
sidered in developing countries. HCV infection was the 
main etiology of HCC throughout the entire observation 
period, including the last two years, at which time 
DAA’s therapy was available in Argentina (since 2014). 
Second, as reported in other regions of the world, fatty 
liver disease was observed as an increasing cause of 
HCC. The prevalence of DBT was significantly higher in 
NAFLD-HCC when compared to non-NAFLD patients. 
Finally, NAFLD-HCC was not associated with a higher 
mortality rate.
In a recently published multicenter Latin American 
retrospective cohort study, the main etiologies of HCC 
were HCV in almost half of the cases, followed by 
alcoholic liver disease, HBV infection and NAFLD in 
nine percent[8]. Another multicenter study from this 
region including HCC LT patients showed that the most 
frequent cause of HCC was HBV[9]. This discrepancies 
show that the reported HCC etiology largely reflects 
country-to-country epidemiological differences. 
Whereas in Brazil the main etiology has been shown 
to be HBV, in Argentina the main HCC etiology has 
been associated with HCV followed by alcoholic liver 
disease[9,10,21]. However, no previous studies have 
evaluated etiologic changes longitudinally. 
It is already known that in developed countries, 
a high-fat diet leads to obesity, insulin resistance, 
metabolic syndrome and type 2 DBT. Unbalanced hyper-
caloric diets, as well as an increasing consumption of 
sugar containing beverages might lead to a profound 
Public Health intervention. These socioeconomically 
changes have been occurring not only in developed but 
also in developing regions worldwide.
NAFLD has been related to an increasing rate of 
overall cardiovascular morbid-mortality[6]. Consequently, 
NAFLD will become responsible of an increase in 
medical resource use in the next years that demands 
specific health prevention programs focusing on diet 
and exercise in order to avoid not only liver but also 
cardiovascular disease development. As previously 
mentioned, a six-fold increase in NAFLD from 2009 to 
2015 was observed in our cohort, mainly in LT centers 
whereas alcoholic liver disease was a leading cause of 
HCC in non­LT centers. This finding has been observed 
in Argentina by other authors[10]. 
DBT leads to fibrosis progression, cirrhosis and 
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Figure 2  Comparative analysis regarding hepatocellular carcinoma previous surveillance and Barcelona Clinic Liver Cancer staging at diagnosis between non 
alcoholic fatty liver disease and other etiologies of liver disease. NAFLD: Non-alcoholic fatty liver disease: Non-NAFLD: Other than NAFLD (includes all other etiologies).
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HCC[6,22,23]. We observed that the increasing prevalence 
of NAFLD-HCC was not in parallel with the increasing 
prevalence of DBT over the years. When we included 
as “potentially NAFLD” those patients with cryptogenic 
cirrhosis with DBT, a similar 6-fold increase since 
2009 to 2015 was observed. Alternatively, we did not 
considered obese patients with cryptogenic cirrhosis as 
probable NAFLD as reported by other authors[24]. In our 
series, body mass index was not recorded. However, 
we performed a sub analysis considering cryptogenic/
DBT patients and NAFLD. Our epidemiological results 
are in line with that from developed countries, 
suggesting that NAFLD would have a major Public 
Health implication in the upcoming years.
Third, from a comparative and specific intergroup 
variability, there were no differences between non-
NAFLD and NAFLD-HCC patients, except from a 
higher prevalence of diabetes mellitus and lower AFP 
values in NAFLD-HCC group. Interestingly, higher AFP 
values were described in other studies in this group of 
patients in comparison to other etiologies[22]. However, 
this significant difference did not impact on patient 
survival, although AFP > 1000 ng/mL at HCC diagnosis 
was an independent predictor of worse survival in the 
multivariate Cox regression analysis. There were no 
major differences in HCC tumor burden between NAFLD 
and non-NAFLD-HCC. Heterogeneous data has been 
published regarding this topic. Some studies described 
tumor differences whereas others did not[25,26].
We acknowledge limitations of cohort studies with 
no control group, in which several factors might be 
biased. However, a strict revision of the data was 
centrally requested, investigators who performed the 
final analysis did not participate in the data collection 
to avoid differential outcome assessment on exposure 
and a complete follow-up and outcome assessment was 
performed in all patients included. Second, the definition 
of NAFLD was mainly based on clinical assessment. 
The lack of histological evaluation of NAFLD and NASH 
in most of the patients might have biased the results. 
However, this clinical definition is accepted worldwide 
by international guidelines[17]. Third, an important 
information or selection bias regarding the lack of body 
mass index has been mentioned earlier regarding 
cryptogenic/obese patients. This might have resulted 
in a lower number of patients in the group of NAFLD 
reported in our study. Finally, combination of different 
etiologies (e.g., alcoholic liver disease plus chronic HCV) 
was not considered in order to include the main factor 
of chronic liver disease. 
In conclusion, NAFLD related HCC has been recog-
nized as a growing burden in the United States and 
in some European regions. This changing etiologic 
scenario has been observed in in high-income countries 
and might even be happening in developing ones. In 
Argentina, even though HCV infection is still the main 
cause of HCC, recent changing trends in etiologies of 
HCC in Argentina suggests that NAFLD might be the 
leading cause of HCC in the next years, becoming an 
important Public Health issue. However, prospective 
studies will be necessary to confirm our findings. 
ARTICLE HIGHLIGHTS
Research background
The incidence of Hepatocellular carcinoma (HCC) has been increasing 
during the last years and is the second leading cause of cancer related death 
worldwide. The cause of HCC is closely linked to the prevalence of chronic 
hepatitis C (HCV) or B virus (HBV) infections as well as the prevalence of 
alcoholic liver disease. With the advent of the new direct antiviral drugs (DAAs) 
for hepatitis C (HCV) treatment, epidemiological changes have been already 
reported in the natural history of liver disease. One of these epidemiological 
changes in developed countries is due to the stepwise increase in the incidence 
of non-alcoholic fatty liver disease (NAFLD), an emergent cause of end stage 
liver disease and HCC. 
Research motivation
Indeed, it is estimated that during the next 20 years, non-alcoholic stea-
tohepatitis (NASH), the progressive form of NAFLD, will constitute the most 
frequent cause of cirrhosis and HCC in developed countries. However, reports 
regarding epidemiological changes of HCC from developing areas, including 
South America, have been heterogeneous and none have focused on changing 
trends in etiologies of HCC over time. 
Research objectives
Our aim was to evaluate changes in the etiology of HCC in Argentina during 
the last seven years, particularly focusing on potential changes associated with 
NAFLD-HCC.
Research methods
This cohort study was conducted between January 1 2009 and January 1 2016 
in 14 regional hospitals from Argentina. Criteria for inclusion required patients 
with newly diagnosed HCC as recommended by international guidelines. 
Etiologies of HCC included viral hepatitis, alcoholic liver disease (alcohol 
intake exceeding 30 g/d), NAFLD, cryptogenic cirrhosis (CC), cholestatic liver 
diseases (i.e., primary biliary cholangitis, primary and secondary sclerosing 
cholangitis), autoimmune hepatitis and other causes including metabolic 
diseases or miscellaneous causes (e.g., hereditary hemochromatosis, Wilson 
disease, toxic liver disease). NAFLD diagnosis was established on histological 
ground or clinically according to international guidelines. Baseline patient and 
tumor characteristics at HCC diagnosis were recorded. Tumor burden was 
classified according to Barcelona Clinic Liver Cancer staging (BCLC criteria). 
Complete patient follow-up was assessed in all included subjects from HCC 
diagnosis until death or last medical visit.
Categorical data were compared using Fisher’s exact test (2-tailed) or Chi-
Square test and continuous variables were compared with Student’s t-test or 
Mann-Whitney U test according to their distribution, respectively. For survival 
analysis, Cox regression multivariate analysis estimating hazard ratios (HR) 
and 95%CI for baseline variables related with 5-year mortality was performed. 
Kaplan Meier survival curves were compared using the log-rank test.
Table 5  Multivariate cox regression analysis of risk factors 
associated with 5-year mortality
Variable HR 95%CI P  value
Age 1.03 1.01; 1.04 < 0.0001
BCLC 0-A 0.50 0.37; 0.68 < 0.0001
Child Pugh B1 1.54 1.61; 2.05  0.003
Child Pugh C1 2.59 1.84; 3.66 < 0.0001
AFP > 1000 ng/mL 2.09 1.52; 2.87 < 0.0001
Tumor vascular invasion 2.84 1.75; 3.53 < 0.0001
1Compared to Child Pugh A, Harrell’s concordance statistic was 0.76. 
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Research results
A total of 708 consecutive adult patients with newly diagnosed HCC from 
14 centers were included. Out of 14 hospitals, 6 were LT centers, which 
contributed with the follow-up of 484 patients (68.4% of the study cohort). Non-
cirrhotic patients accounted for 12.6% of the included cohort (n = 89). The 
prevalence of diabetes mellitus (DBT) was 27.7%. Between 2009 and 2016, 
HCV related HCC was the most frequent etiology along the whole observation 
period. No significant changes were observed in the proportion of HCV-
HCC. The second most frequent cause of HCC was alcoholic liver disease, 
remaining stable along the observation period. On the other hand, a striking 
6-fold increase in the proportion of HCC-NAFLD cases was observed since 
2009 to 2016 (4.3% vs 25.6%; P < 0.0001). NAFLD was the second cause of 
HCC in 2015 together with alcoholic liver disease. In addition, when patients 
with cryptogenic cirrhosis/liver disease and DBT (n = 22/68) were considered 
together as potentially metabolic syndrome/NAFLD, the NAFLD/Cryptogenic 
+ DBT group represented 14.5% (n = 103) of the entire cohort and increased 
from 8.6% in 2009 to 16.2% in 2014 and 25.6% in 2016, respectively (P = 
0.014). There was a higher prevalence of diabetes mellitus (DBT) (61.7% vs 
non-NAFLD 23.3%; P < 0.0001) in the NAFLD group. The increasing proportion 
of NAFLD in the overall cohort was not in parallel with an increase of DBT in 
this population. On the other hand, lower median AFP values at HCC diagnosis 
were observed between NAFLD-HCC and non-NAFLD groups (6.6 ng/mL vs 
26 ng/mL; P = 0.02). Neither NAFLD nor other HCC etiologies were associated 
with higher mortality.
Research conclusions
To the best of our knowledge this is the first multicenter cohort study from a 
South American country evaluating longitudinal changes in etiologic trends. This 
changing etiologic scenario documented in developed countries is replicated 
in developing ones. The documented increase in NAFLD-HCC in our study 
including a developing country entails in itself a challenging impact on Public 
Health worth to be considered. HCV infection was the main etiology of HCC 
throughout the entire observation period, including the last two years, at which 
time DAA’s therapy was available in Argentina. Second, as reported in other 
regions of the world, fatty liver disease was observed as an increasing cause 
of HCC. The prevalence of DBT was significantly higher in NAFLD-HCC when 
compared to non-NAFLD patients. Finally, NAFLD-HCC was not associated 
with an increasing risk of mortality, adjusted for the presence HCC surveillance 
and BCLC stage. NAFLD has been related to an increasing rate of overall 
cardiovascular morbid-mortality. Consequently, NAFLD will become responsible 
of an increase in medical resource use in the next years that demands specific 
health prevention programs focusing in diet and exercise in order to avoid 
not only liver but also cardiovascular disease development. As previously 
mentioned, a six-fold increase in NAFLD from 2009 to 2015 was observed in 
our cohort, mainly in LT centers whereas alcoholic liver disease was a leading 
cause of HCC in non-LT centers. 
Research perspectives
NAFLD related HCC has been recognized as a growing burden in the United 
States and some European regions. This etiologic scenario is not only changing 
in high-income countries but also it might be happening in developing ones. In 
Argentina, even though HCV infection is still the main cause of HCC, recent 
changing trends in etiology of HCC in Argentina suggests that NAFLD might be 
the leading HCC cause in the next years, becoming an important Public Health 
issue. 
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